We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.63%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$659M
AUM Growth
-$194M
Cap. Flow
-$205M
Cap. Flow %
-31.16%
Top 10 Hldgs %
43.01%
Holding
164
New
28
Increased
30
Reduced
27
Closed
56

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$15.1M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.4M
3
FOLD
Amicus Therapeutics
FOLD
+$11.3M
4
NMTR
9 Meters Biopharma
NMTR
+$9.54M
5
MRK icon
Merck
MRK
+$8.77M

Top Sells

Rank Stock Value
1
CEL
Cellcom Israel, Ltd.
CEL
+$14M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.9M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$9.22M
4
RXDX
Ignyta, Inc.
RXDX
+$9.19M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.07M

Sector Composition

Rank Sector Weight
1 Healthcare 75.21%
2 Technology 4.55%
3 Financials 1.71%
4 Communication Services 1.32%
5 Consumer Discretionary 0.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
26
DELISTED
Array Biopharma Inc
ARRY
$6.61M 1%
405,000
– –
PTLA
27
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$6.53M 0.99%
+200,000
New +$8.78M
ARQL
28
DELISTED
Arqule Inc
ARQL
$6.52M 0.99%
+2,264,136
New +$4.3M
MNOV icon
29
MediciNova
MNOV
$65.5M
$6.45M 0.98%
+630,838
New +$6.29M
NICE icon
30
Nice
NICE
$5.79B
$6.37M 0.97%
67,758
-40,112
-37% -$3.74M
KDMN
31
DELISTED
Kadmon Holdings, Inc.
KDMN
$6.33M 0.96%
1,490,000
+390,000
+35% +$1.67M
ASND icon
32
Ascendis Pharma A/S
ASND
$16B
$6.24M 0.95%
95,474
-34,000
-26% -$1.91M
KURA icon
33
Kura Oncology
KURA
$800M
$6.19M 0.94%
+330,000
New +$6.42M
MSFT icon
34
Microsoft
MSFT
$3.45T
$6.1M 0.93%
+66,850
New +$6.11M
TSRO
35
DELISTED
TESARO, Inc.
TSRO
$6.07M 0.92%
106,175
+11,175
+12% +$719K
RCKT icon
36
Rocket Pharmaceuticals
RCKT
$340M
$5.67M 0.86%
302,275
+277,165
+1,104% +$4.52M
PVLA
37
Palvella Therapeutics
PVLA
$1.99B
$5.46M 0.83%
10,000
– –
CTMX icon
38
CytomX Therapeutics
CTMX
$675M
$5.12M 0.78%
180,000
+20,000
+13% +$571K
FLEX icon
39
Flex
FLEX
$41.7B
$5.03M 0.76%
+408,502
New +$5.57M
DK icon
40
Delek US
DK
$4.16B
$4.98M 0.76%
+122,284
New +$4.4M
GOOGL icon
41
Alphabet (Google) Class A
GOOGL
$4.36T
$4.97M 0.75%
95,840
-19,500
-17% -$1.08M
TVTX icon
42
Travere Therapeutics
TVTX
$5.2B
$4.92M 0.75%
+220,000
New +$5.24M
NERV icon
43
Minerva Neurosciences
NERV
$185M
$4.84M 0.74%
96,875
– –
V icon
44
Visa
V
$684B
$4.83M 0.73%
40,401
-20,000
-33% -$2.42M
EIGR
45
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.68M 0.71%
15,833
-1,216
-7% -$359K
RETA
46
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$4.62M 0.7%
225,000
– –
ALNA
47
DELISTED
Allena Pharmaceuticals
ALNA
$4.52M 0.69%
410,199
+85,199
+26% +$712K
SNDX icon
48
Syndax Pharmaceuticals
SNDX
$1.69B
$4.25M 0.64%
298,472
+50,000
+20% +$531K
ABEO icon
49
Abeona Therapeutics
ABEO
$366M
$4.23M 0.64%
11,800
+3,400
+40% +$1.26M
PBYI icon
50
Puma Biotechnology
PBYI
$404M
$4.08M 0.62%
60,000
+25,000
+71% +$1.87M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sphera Funds Management held 164 positions worth $659M, down 23% from $852M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Sphera Funds Management withdrew a net $205M in Q1 2018, closing 56 positions and reducing 27 holdings. Its most notable exit was Cellcom Israel, Ltd., an estimated $14M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 59% a quarter earlier, followed by Technology and Financials.

Against the trend, Sphera Funds Management opened a new position in Regeneron Pharmaceuticals worth $14.3M.

  • Sphera Funds Management's largest Q1 2018 buy was Regeneron Pharmaceuticals: 41,500 shares worth $14.3M.
  • Sphera Funds Management added most to Shire pic in Q1 2018, an estimated $15.1M increase.
  • Sphera Funds Management's biggest Q1 2018 reduction was Sarepta Therapeutics, cutting an estimated $9.07M.
  • Sphera Funds Management fully exited Cellcom Israel, Ltd. in Q1 2018, selling an estimated $14M.
  • Sphera Funds Management's ten largest holdings make up 43% of its $659M portfolio in Q1 2018.
  • Sphera Funds Management opened 28 new positions and closed 56 in Q1 2018.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $659M.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.